Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450537 | 0.93 | DGKA (0.52) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8896962 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8812077 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8895560 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8894824 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8894556 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL938866 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8893734 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8849361 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 | |
| SCHEMBL8895726 | 0.91 | DGKA (0.55) | CES1CES2DGKATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| CN-115427081-A | Drug antibody conjugates | 法马马有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-4025253-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar S.A. (ES) | 2022-07-13 | — | — | EP | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2022-06-02 | — | — | US | disclosed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0725074-A2 | Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives | SANKYO COMPANY LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5459148-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | CD79B, OGFR, CD2 | CES1 1419/4885CES2 1950/4885DGKA 3973/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | CES1 1910/4885CES2 2410/4885DGKA 2103/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | CES1 2540/4885CES2 2565/4885DGKA 3707/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | CES1 515/4885CES2 1874/4885DGKA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.